These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7429331)

  • 1. Treatment of bone disease after jejunoileal bypass for obesity with oral 1 alpha-hydroxyvitamin D3.
    Compston JE; Horton LW; Laker MF; Merrett AL; Woodhead JS; Gazet JC; Pilkington TR
    Gut; 1980 Aug; 21(8):669-74. PubMed ID: 7429331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic osteomalacia after jejunoileal bypass surgery in a patient with primary hyperparathyroidism. A study of the change in bone morphology and vitamin D metabolites before and during treatment.
    Taylor HC; Teitelbaum SL; Lambert PW
    Gastroenterology; 1983 Sep; 85(3):735-42. PubMed ID: 6603388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone disease after jejuno-ileal bypass for obesity.
    Compston JE; Horton LW; Laker MF; Ayers AB; Woodhead JS; Bull HJ; Gazet JC; Pilkington TR
    Lancet; 1978 Jul; 2(8079):1-4. PubMed ID: 78209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Musculo-skeletal abnormalities after jejunoileal bypass.
    Pilkington TR; Gazet JC; Compston JE; Kennedy C
    Int J Obes; 1981; 5(5):509-12. PubMed ID: 7309333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral 25-hydroxyvitain D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy.
    Compston JE; Horton LW
    Gastroenterology; 1978 May; 74(5 Pt 1):900-2. PubMed ID: 640344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low serum levels of 1.25-dihydroxyvitamin D and histomorphometric evidence of osteomalacia after jejunoileal bypass for obesity.
    Mosekilde L; Melsen F; Hessov I; Christensen MS; Lund BJ; Lund BI; Sørensen OH
    Gut; 1980 Jul; 21(7):624-31. PubMed ID: 7429327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
    Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
    Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of osteomalacia associated with primary biliary cirrhosis with parenteral vitamin D2 or oral 25-hydroxyvitamin D3.
    Compston JE; Horton LW; Thompson RP
    Gut; 1979 Feb; 20(2):133-6. PubMed ID: 311747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral 1alpha-hydroxyvitamin D3 in the treatment of osteomalacia associated with malabsorption.
    Compston JE; Horton LW; Tighe JR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():245s-246s. PubMed ID: 606421
    [No Abstract]   [Full Text] [Related]  

  • 10. Osteomalacia and weakness complicating jejunoileal bypass.
    Franck WA; Hoffman GS; Davis JS; Alpern HD; Olson JE
    J Rheumatol; 1979; 6(1):51-6. PubMed ID: 439111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed fracture healing following jejunoileal bypass surgery for obesity.
    Hey H; Lund B; Sørensen OH; Lund B
    Calcif Tissue Int; 1982 Jan; 34(1):13-5. PubMed ID: 6802454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of osteomalacia with oral 1-alpha-hydroxyvitamin D3 in a patient with malabsorption.
    Compston JE; Horton LW; Tighe JR
    Br Med J; 1977 Sep; 2(6087):612. PubMed ID: 902001
    [No Abstract]   [Full Text] [Related]  

  • 13. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal abnormalities after jejunoileal bypass.
    Halverson JD; Teitelbaum SL; Haddad JG; Murphy WA
    Ann Surg; 1979 Jun; 189(6):785-90. PubMed ID: 453949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of dialysate calcium concentration on 1alpha-hydroxyvitamin D3 on skeletal calcium loss and hyperparathyroidism in haemodialysis patients.
    Winney RJ; Tothill P; Robson JS; Abbot SR; Lidgard GP; Cameron EH; Smith MA; Macpherson HN; Strong JA
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():151s-158s. PubMed ID: 606413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
    Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
    Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated bone phosphorus/hydroxyproline ratio following jejunoileal bypass surgery.
    Hey H; Tougaard L
    Acta Med Scand; 1980; 208(4):321-3. PubMed ID: 7446210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
    Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with high-dose oral vitamin D2 in patients with jejunoileal bypass for morbid obesity. Effects on calcium and magnesium metabolism, vitamin D metabolites, and faecal lag time.
    Charles P; Mosekilde L; Søndergård K; Jensen FT
    Scand J Gastroenterol; 1984 Nov; 19(8):1031-8. PubMed ID: 6335925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D.
    Reed JS; Meredith SC; Nemchausky BA; Rosenberg IH; Boyer JL
    Gastroenterology; 1980 Mar; 78(3):512-7. PubMed ID: 7351289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.